CD Bioparticles announces custom nucleic acid delivery particle synthesis services for gene therapy, gene editing, vaccines and immunotherapy.
(PRUnderground) May 27th, 2025
With years of experience in the pharmaceutical and life science sectors, CD Bioparticles has announced its custom nucleic acid delivery particle synthesis services for the advancement of gene therapy, gene editing, vaccines and immunotherapy. These new offerings, such as the synthesis of basic particles, can address the growing need for safe and efficient delivery of gene therapy materials.
CD Bioparticles offers various customized services to help researchers develop nanoparticle-based drug targeting and delivery systems. Targeted drug delivery is a strategy that selectively delivers therapeutic agents to the target site preferentially and reduces drug accumulation at off-target sites. Specific ligands are often used to facilitate the localization of therapeutic molecules to target tissues. Ligand-targeted chemotherapeutics, photothermal therapies, and other therapies have been developed based on the affinity between ligands and receptors that are naturally expressed or overexpressed in cancer cells.
In this way, normal tissues are not harmed by anticancer drugs and the effective concentration of anticancer drugs is reduced. These ligands can be small molecules (e.g., carbohydrates, folic acid), low-density lipoproteins (LDL), aptamers, peptides, and proteins (e.g., transferrin or antibodies).
As technology advances, there is a growing need for a safe and efficient way to deliver gene therapy materials. Nanomaterials for nucleic acid delivery are attractive because of their diverse physicochemical properties and selective targeting by conjugation to biomolecules. Nucleic acid therapeutics such as antisense DNA, mRNA, small interfering RNA (siRNA) or microRNA (miRNA) have been widely used to modulate the expression of DNA or RNA for bioanalysis, gene silencing, protein replacement and vaccines.
CD Bioparticles addresses this by leveraging its expertise in nanoparticle synthesis to create custom delivery systems tailored to specific applications. The newly launched services focus on polymeric and inorganic particles, which are widely recognized for their good physicochemical properties and the ability to precisely design size, shape and surface features. The company also offers a wide range of functionalized and conjugated products to assist researchers for successful delivery.
The new custom services cover the entire process, including synthesis of basic particles, functionalization and conjugation of molecules for targeted delivery, and encapsulation or coupling of nucleic acids to particles. These custom nucleic acid delivery particles are applicable in a wide range of fields, including bioanalysis, gene silencing, gene editing, vaccine development, immunotherapy, and the creation of advanced nucleic acid nano-barcodes.
The company works closely with clients, requesting details such as intended application, type of base particle, desired particle diameter, specific functionalization or conjugation requirements, cargo details, quantity, format, and quality control requirements to ensure the final product meets the precise specifications of each project.
Researchers and therapeutic developers interested in learning more about CD Bioparticles’ custom nucleic acid delivery particle synthesis services, please visit https://www.cd-bioparticles.com/services/nucleic-acid-delivery-particles.html.
About CD Bioparticles
CD Bioparticles specializes in manufacturing and supplying nanoparticles, microparticles, and coatings for diagnostics and research, alongside developing customized, biocompatible drug delivery systems. We offer diverse formulation technologies (from liposomes to polymer nanoparticles) and comprehensive services, including surface functionalization, antibody immobilization, and contract research for drug delivery.
The post CD Bioparticles Launches Custom Nucleic Acid Delivery Particle Synthesis Services to Accelerate Gene Therapy and Research first appeared on
Original Press Release.
